-
Pesticide exposure and increased risk of breast cancer for women in rural Brazil Lancet Oncol. (IF 41.6) Pub Date : 2024-12-19 Karl Gruber
No Abstract
-
Unveiling the mysteries of extrachromosomal circular DNA: from generation to clinical relevance in human cancers and health Mol. Cancer (IF 27.7) Pub Date : 2024-12-20 Zilong Wang, Jiaying Yu, Wenli Zhu, Xiaoning Hong, Zhen Xu, Shuang Mao, Lei Huang, Peng Han, Chunxiao He, Changze Song, Xi Xiang
Extrachromosomal circular DNAs (eccDNAs) are a type of circular DNAs originating from but independent of chromosomal DNAs. Nowadays, with the rapid development of sequencing and bioinformatics, the accuracy of eccDNAs detection has significantly improved. This advancement has consequently enhanced the feasibility of exploring the biological characteristics and functions of eccDNAs. This review elucidates
-
AI-based classification of anticancer drugs reveals nucleolar condensation as a predictor of immunogenicity Mol. Cancer (IF 27.7) Pub Date : 2024-12-20 Giulia Cerrato, Peng Liu, Liwei Zhao, Adriana Petrazzuolo, Juliette Humeau, Sophie Theresa Schmid, Mahmoud Abdellatif, Allan Sauvat, Guido Kroemer
Immunogenic cell death (ICD) inducers are often identified in phenotypic screening campaigns by the release or surface exposure of various danger-associated molecular patterns (DAMPs) from malignant cells. This study aimed to streamline the identification of ICD inducers by leveraging cellular morphological correlates of ICD, specifically the condensation of nucleoli (CON). We applied artificial intelligence
-
Correction to Lancet Oncol 2024; published online Dec 12. https://doi.org/10.1016/S1470-2045(24)00719-8 Lancet Oncol. (IF 41.6) Pub Date : 2024-12-18
Gruber K. Prior authorisation is can harm patients with cancer in the USA. Lancet Oncol 2024; published online Dec 12. https://doi.org/10.1016/S1470-2045(24)00719-8—In this News story, there was a typographical error in the title. This correction has been made to the online version as of Dec 18, 2024, and will be made to the printed version.
-
Integrating cancer into crisis: a global vision for action from WHO and partners Lancet Oncol. (IF 41.6) Pub Date : 2024-12-18 Raffaella Casolino, Richard Sullivan, Kiran Jobanputra, May Abdel-Wahab, Miljana Grbic, Nazik Hammad, Tezer Kutluk, Nelya Melnitchouk, Alexandra Mueller, Roberta Ortiz, Diana Paez, Omar Shamieh, Gevorg Tamamyan, Horia Vulpe, Bente Mikkelsen, Andrè Ilbawi, Slim Slama
More than a billion people live in fragile, conflict-affected, and vulnerable settings requiring humanitarian support, where cancer is a substantial health issue. Despite its substantial effect on populations, cancer care remains underprioritised in emergency preparedness and response frameworks and humanitarian operational planning. This Policy Review summarises the perspectives and actionable recommendations
-
ZDHHC20 mediated S-palmitoylation of fatty acid synthase (FASN) promotes hepatocarcinogenesis Mol. Cancer (IF 27.7) Pub Date : 2024-12-19 Yaqi Mo, Yamei Han, Yang Chen, Chunling Fu, Qing Li, Zhuang Liu, Mingming Xiao, Bo Xu
Protein palmitoylation is a reversible fatty acyl modification that undertakes important functions in multiple physiological processes. Dysregulated palmitoylations are frequently associated with the formation of cancer. How palmitoyltransferases for S-palmitoylation are involved in the occurrence and development of hepatocellular carcinoma (HCC) is largely unknown. Chemical carcinogen diethylnitrosamine
-
Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy Mol. Cancer (IF 27.7) Pub Date : 2024-12-19 Menglai Gan, Nanshu Liu, Wenting Li, Mingwei Chen, Zhongyu Bai, Dongjuan Liu, Sai Liu
Oral squamous cell carcinoma (OSCC) is a prevalent oral malignancy, which poses significant health risks with a high mortality rate. Regulatory T cells (Tregs), characterized by their immunosuppressive capabilities, are intricately linked to OSCC progression and patient outcomes. The metabolic reprogramming of Tregs within the OSCC tumor microenvironment (TME) underpins their function, with key pathways
-
Government Funding for the Development of Enzalutamide JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Bishal Gyawali, Emily H. Jung, Helen Mooney, Jerry Avorn, Aaron S. Kesselheim
This cross-sectional study assesses the various patents and US government grants that were critical to the publicly funded development of the cancer drug enzalutamide.
-
Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Laura A. Dawson, Kathryn A. Winter, Jennifer J. Knox, Andrew X. Zhu, Sunil Krishnan, Chandan Guha, Lisa A. Kachnic, Michael T. Gillin, Theodore S. Hong, Timothy D. Craig, Terence M. Williams, Ali Hosni, Eric Chen, Anne M. Noonan, Eugene J. Koay, Rishi Sinha, Michael I. Lock, Nitin Ohri, Jennifer A. Dorth, Guila Delouya, Anand Swaminath, Jennifer Moughan, Christopher H. Crane
ImportanceMost patients with locally advanced hepatocellular carcinoma (HCC) recur within the liver following systemic therapy.ObjectiveTo determine whether stereotactic body radiation therapy (SBRT) improves outcomes in patients with locally advanced HCC compared with sorafenib alone.Design, Setting, and ParticipantsThis multicenter phase 3 randomized clinical trial randomized patients with HCC 1:1
-
Assessing the Risk of Radiation Myelitis in Hypofractionated Stereotactic Body Radiation Therapy-Tolerance Is in the Eye of the Beholder. JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Evangelia Katsoulakis,Daniel E Spratt
-
Radiation Myelitis Risk After Hypofractionated Spine Stereotactic Body Radiation Therapy JAMA Oncol. (IF 22.5) Pub Date : 2024-12-19 Christopher B. Jackson, Lillian A. Boe, Lei Zhang, Aditya Apte, Lisa M. Ruppert, Justin M. Haseltine, Boris A. Mueller, Adam M. Schmitt, Jonathan T. Yang, W. Christopher Newman, Ori Barzilai, Mark H. Bilsky, Yoshiya Yamada, Andrew Jackson, Eric Lis, Daniel S. Higginson
ImportanceStereotactic body radiation therapy (SBRT) for spinal metastases improves symptomatic outcomes and local control compared to conventional radiotherapy. Treatment failure most often occurs within the epidural space, where dose is constrained by the risk of radiation myelitis (RM). Current constraints designed to prevent RM after spine SBRT are derived from limited data.ObjectiveTo characterize
-
THE STING AGONIST VB-85247 INDUCES DURABLE ANTITUMOR IMMUNE RESPONSES BY INTRAVESICAL ADMINISTRATION IN A NON-MUSCLE INVASIVE BLADDER CANCER Cancer Res. (IF 12.5) Pub Date : 2024-12-19 Miglena G. Prabagar, Michael McQueney, Venu Bommireddy, Rachael Siegel, Gary L. Schieven, Ku Lu, Ruziboy Husanov, Reema Deepak, David Diller, Chia-Yu Huang, Eli Mordechai, Rukiye-Nazan Eraslan
Bacillus Calmette-Guerin (BCG) is the current standard of care for non-muscle invasive bladder cancer (NMIBC), but recurrence is common. Additional therapeutic options are a major unmet medical need for treating unresponsive patients. Stimulator of Interferon Genes (STING) plays a central role in mounting innate and adaptive immune responses to tumor cells, and activation of STING is a promising immunotherapeutic
-
DOT1L mediates stem cell maintenance and represents a therapeutic vulnerability in cancer Cancer Res. (IF 12.5) Pub Date : 2024-12-19 Hetakshi P. Kurani, Joyce M. Slingerland
Tumor-initiating cancer stem cells (CSC) pose a challenge in human malignancies since they are largely treatment resistant and can seed local recurrence and metastasis. Epigenetic mechanisms governing cell fate decisions in embryonic and adult stem cells are deregulated in CSCs. This review focuses on the methyltransferase DOT1L, which methylates H3K79 and is a key epigenetic regulator governing embryonic
-
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer Cancer Res. (IF 12.5) Pub Date : 2024-12-19 Jeremy B. Foote, Tyler E. Mattox, Adam B. Keeton, Xi Chen, Forrest T. Smith, Kristy Berry, Thomas W. Holmes, Junwei Wang, Chung-hui Huang, Antonio Ward, AMIT K. Mitra, Veronica Ramirez-Alcantara, Cherlene Hardy, Karianne G. Fleten, Kjersti Flatmark, Karina J. Yoon, Sujith Sarvesh, Ganji P. Nagaraju, Dhana Sekhar Reddy Bandi, Yulia Y. Maxuitenko, Jacaob Valiyaveettil, Julienne L. Carstens, Donald J
RAS is a common driver of cancer that was considered undruggable for decades. Recent advances have enabled the development of RAS inhibitors, but the efficacy of these inhibitors remains limited by resistance. Here, we developed a pan-RAS inhibitor, ADT-007, that binds nucleotide-free RAS to block GTP activation of effector interactions and MAPK/AKT signaling, resulting in mitotic arrest and apoptosis
-
Spatiotemporal Profiling Defines Persistence and Resistance Dynamics During Targeted Treatment of Melanoma Cancer Res. (IF 12.5) Pub Date : 2024-12-19 Jill C. Rubinstein, Sergii Domanskyi, Todd B. Sheridan, Brian Sanderson, SungHee Park, Jessica Kaster, Haiyin Li, Olga Anczukow, Meenhard Herlyn, Jeffrey H. Chuang
Resistance of BRAF-mutant melanomas to targeted therapy arises from the ability of cells to enter a persister state, evade treatment with relative dormancy, and repopulate the tumor when reactivated. A better understanding of the temporal dynamics and specific pathways leading into and out of the persister state is needed to identify strategies to prevent treatment failure. Using spatial transcriptomics
-
Selenoprotein O Promotes Melanoma Metastasis and Regulates Mitochondrial Complex II Activity Cancer Res. (IF 12.5) Pub Date : 2024-12-19 Luiza Martins. Nascentes Melo, Marie Sabatier, Vijayashree Ramesh, Krystina J. Szylo, Cameron S. Fraser, Alexandra Pon, Evann C. Mitchell, Kelly A. Servage, Gabriele Allies, Isa V. Westedt, Feyza Cansiz, Jonathan Krystkiewicz, Andrea Kutritz, Dirk Schadendorf, Sean J. Morrison, Jessalyn M. Ubellacker, Anju Sreelatha, Alpaslan Tasdogan
Evolutionarily conserved selenoprotein O (SELENOO) catalyzes a post-translational protein modification known as AMPylation that is essential for the oxidative stress response in bacteria and yeast. Given that oxidative stress experienced in the blood limits survival of metastasizing melanoma cells, SELENOO might be able to impact metastatic potential. However, further work is needed to elucidate the
-
Comparison of Shared Class I HLA-bound Non-canonical Neoepitopes between Normal and Neoplastic Tissues of Pancreatic Adenocarcinoma Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-19 Tengyi Zhang, Betul Celiker, Yingkuan Shao, Jessica Gai, C. Mark Hill, Chunyu Wang, Lei Zheng
Purpose: Developing T cell or vaccine therapies for pancreatic ductal adenocarcinoma (PDAC) has been challenging due to a lack of knowledge regarding immunodominant, cancer-specific antigens, as a scarcity of genomic mutation-associated neoepitopes characterizes PDAC and there are limited availability of effective approaches to discover them. Experimental Design: We utilized an advanced mass spectrometry
-
Histologic and immunologic factors associated with response to immune checkpoint inhibitors in advanced sarcoma Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-19 Alex Q. Lee, Clara Hao, Minggui Pan, Kristen N. Ganjoo, Nam Q. Bui
Purpose: To characterize factors associated with response to immune checkpoint inhibitors (ICIs) in advanced sarcoma. Experimental Design: This is a retrospective study with a cohort of 216 patients with advanced sarcoma treated with ICIs between 2016-2023 at Stanford Health Care. Overall survival (OS), progression free survival (PFS), objective response rates per RECIST criteria (ORR), and reason
-
Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-19 Ann Oluloro, Elizabeth M Swisher, Heidi J Gray, Barbara Goff, Kemi M Doll
Background Racial and ethnic minorities remain underrepresented in gynecologic cancer clinical trials despite disproportionately worse oncologic outcomes. Research shows differential racial enrollment patterns due to comorbidity-based exclusion criteria (CEC). Our objective was to evaluate contemporary trends in CECs among NCI-sponsored gynecologic cancer clinical trials and protocol adherence to broadened
-
Reducing-a little-the high price of randomized trials of the efficacy of multicancer early detection. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-19 Noel S Weiss
-
Testing stored control-arm specimens could dramatically increase statistical power yet reduce costs in cancer screening trials. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-19 Hormuzd A Katki
-
The widespread application of trans-oral robotic surgery in HPV-related head and neck cancer: one size does not fit all. J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-19 Mihir R Patel,Barbara Burtness,Robert L Ferris,Nabil F Saba
-
Circular RNA circPHLPP2 promotes tumor growth and anti-PD-1 resistance through binding ILF3 to regulate IL36γ transcription in colorectal cancer Mol. Cancer (IF 27.7) Pub Date : 2024-12-18 Yan Hu, Ze-Rong Cai, Ren-Ze Huang, De-Shen Wang, Huai-Qiang Ju, Dong-Liang Chen
Most Colorectal Cancer (CRC) patients exhibit limited responsiveness to anti-programmed cell death protein 1 (PD-1) therapy, with the underlying mechanisms remaining elusive. Circular RNAs (circRNAs) play a significant role in tumorigenesis and development, with potential applications in tumor screening and predicting treatment efficacy. However, there are few studies exploring the role of circRNAs
-
Incidence, risk factors, and epidemiological trends of tracheal cancer: a global analysis Mol. Cancer (IF 27.7) Pub Date : 2024-12-18 Junjie Huang, Mingtao Chen, Lin Zhang, Xu Lin, Don Eliseo Lucero-Prisno, Claire Chenwen Zhong, Wanghong Xu, Zhi-Jie Zheng, Mellissa Withers, Martin C. S. Wong
Tracheal cancer is a rare malignancy with limited research but high mortality rates. This study aims to analyse recent data to understand the global burden, trends, and risk factors for tracheal cancer, facilitating improved prevention and treatment strategies. We conducted a study on tracheal cancer using data from the Global Cancer Observatory and the Cancer Incidence in Five Continents databases
-
Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL Nat. Rev. Clin. Oncol. (IF 81.1) Pub Date : 2024-12-17 Peter Sidaway
Despite considerable progress, B-cell acute lymphoblastic leukaemia (B-ALL) remains a major cause of cancer-related death in children. Now, data from the phase III AALL1731 trial demonstrate that adding the CD19 × CD3 bispecific T cell engager blinatumomab to chemotherapy significantly improves the outcomes of patients with standard-risk B-ALL with an average or high risk of disease relapse. In this
-
Stratified Medicine Paediatrics: Cell free DNA and serial tumour sequencing identifies subtype specific cancer evolution and epigenetic states Cancer Discov. (IF 29.7) Pub Date : 2024-12-18 Sally L. George, Claire Lynn, Reda Stankunaite, Debbie Hughes, Carolin M. Sauer, Jane Chalker, Saira Waqar Ahmed, Minou Oostveen, Paula Z. Proszek, Lina Yuan, Ridwan Shaikh, Sabri Jamal, Ama Brew, Jennifer Tall, Tony Rogers, Steven C. Clifford, Josef Vormoor, Janet M. Shipley, Deborah A. Tweddle, Chris Jones, Courtney Willis, G.A. Amos Burke, Aditi Vedi, Lisa Howell, Robert Johnston, Helen Rees, Madeleine
We profiled a large heterogenous cohort of matched diagnostic-relapse tumour tissue and paired plasma-derived cell free DNA (cfDNA) from patients with relapsed and progressive solid tumours of childhood. Tissue and cfDNA sequencing results were concordant, with a wider spectrum of mutant alleles and higher degree of intra-tumour heterogeneity captured by the latter, if sufficient circulating tumour-derived
-
CLK1 Activates YAP to Promote Intrahepatic Cholangiocarcinogenesis Cancer Res. (IF 12.5) Pub Date : 2024-12-18 Shuai Xue, Xiangzheng Chen, Guoteng Qiu, Haotian Liao, Zeyuan Qiang, Zheng Zhang, Xuping Feng, Lin Xu, Rui Xie, Hongyu Zhou, Jiwei Huang, Yong Zeng, Haichuan Wang
Cdc2-like kinase 1 (CLK1) has dual-specificity kinase ability to phosphorylate tyrosine and serine/threonine protein residues. CLK1 regulates many physiological processes and has been shown to contribute to multiple types of cancer. Here, we investigated the functional role of CLK1 during intrahepatic cholangiocarcinoma (ICC) development. The expression of CLK1 was elevated in ICC tumors, and patients
-
Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal Cancer Cancer Res. (IF 12.5) Pub Date : 2024-12-18 Joan Jacob, Yasuaki Anami, Peyton C. High, Zhengdong Liang, Shraddha Subramanian, Sukhen C. Ghosh, Solmaz AghaAmiri, Cara Guernsey-Biddle, Ha Tran, Julie Rowe, Ali Azhdarinia, Kyoji Tsuchikama, Kendra S. Carmon
As colorectal cancer (CRC) remains a leading cause of cancer-related death, identifying therapeutic targets and approaches is essential to improve patient outcomes. The EGFR ligand epiregulin (EREG) is highly expressed in RAS wildtype and mutant CRC with minimal expression in normal tissues, making it an attractive target for antibody-drug conjugate (ADC) development. In this study, we produced and
-
The landscape of primary mismatch repair deficient gliomas in children, adolescents, and young adults: a multi-cohort study Lancet Oncol. (IF 41.6) Pub Date : 2024-12-16 Logine Negm, Jiil Chung, Liana Nobre, Julie Bennett, Nicholas R Fernandez, Nuno Miguel Nunes, Zhihui Amy Liu, Martin Komosa, Melyssa Aronson, Cindy Zhang, Lucie Stengs, Vanessa Bianchi, Melissa Edwards, Sheradan Doherty, Ayse Bahar Ercan, Maria F Cardenas, Michael Macias, Matthew R Lueder, Michelle Ku, Monique Johnson, Uri Tabori
BackgroundGliomas are a major cause of cancer-related death among children, adolescents, and young adults (age 0–40 years). Primary mismatch repair deficiency (MMRD) is a pan-cancer mechanism with unique biology and therapeutic opportunities. We aimed to determine the extent and impact of primary MMRD in gliomas among children, adolescents, and young adults. MethodsClinical and molecular data were
-
The changing global landscape of national cancer control plans Lancet Oncol. (IF 41.6) Pub Date : 2024-12-16 Yannick Romero, Zuzanna Tittenbrun, Dario Trapani, Leslie Given, Karin Hohman, Mishka Kohli Cira, Kalina Duncan, Andre Ilbawi, Lisa M Stevens
Global efforts to highlight cancer and non-communicable diseases (NCDs) as a growing burden were first raised in 2005 World Health Assembly Resolution 58.22 and reinforced with Resolution 70.12 and the Global NCD action plan in 2017. One common thread for addressing cancer burden was the need to articulate cancer priorities within a comprehensive national cancer control plan (NCCP). Since 2012, the
-
Circulating tumor DNA dynamics and clinical outcome in metastatic colorectal cancer patients undergoing front-line chemotherapy Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-17 Michele Ghidini, Jens C. Hahne, Chiara Senti, Timon Heide, Paula Z. Proszek, Ridwan Shaikh, Paul Carter, Michael Hubank, Francesco Trevisani, Ornella Garrone, Maria Rosa Cappelletti, Daniele Generali, Monica Cattaneo, Nicoletta Gnocchi, Gianvito Donati, Angela Gobbi, Giulia Grizzi, Andrea Lampis, Raghad Elghadi, Giulia Tanzi, Gianluca Tomasello, Margherita Ratti, David J. Pinato, Matteo Fassan, Georgios
Purpose: we tested whether ctDNA changes may be used to assess early response and clinical outcome in metastatic colorectal cancer (mCRC) patients undergoing front-line systemic anti-cancer therapy (SACT). Experimental Design: 862 plasma samples were collected 4-weekly from baseline (BL) until disease progression in mCRC patients receiving front line SACT. ctDNA normalization was defined as ≥99% clearance
-
Drinking pattern and time lag of alcohol consumption with colorectal cancer risk in US men and women J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-17 Xinyi Li, Jinhee Hur, Yin Zhang, Mingyang Song, Stephanie A Smith-Warner, Liming Liang, Kenneth J Mukamal, Eric B Rimm, Edward L Giovannucci
Background Association between light to moderate alcohol consumption and colorectal cancer (CRC) incidence remains understudied, especially regarding drinking pattern, beverage type and temporal aspects. Methods Hazard ratios (HRs) and 95% confidence intervals (CIs) for time to CRC diagnosis were estimated among 137,710 participants. Estimates based on remote (eg, >10 years before follow-up) and recent
-
Conventional chemotherapy: millions of cures, unresolved therapeutic index Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-12-16 Anthony Letai, Hugues de The
-
PDX models for functional precision oncology and discovery science Nat. Rev. Cancer (IF 72.5) Pub Date : 2024-12-16 Zannel Blanchard, Elisabeth A. Brown, Arevik Ghazaryan, Alana L. Welm
-
C-Reactive Protein Facilitates Premetastatic Niche Formation in the Lungs Cancer Res. (IF 12.5) Pub Date : 2024-12-16 Jonas Saal, Niklas Klümper, Michael Hölzel
C-reactive protein (CRP) has long been recognized as a marker of inflammation, but its evolving role in immunomodulation and cancer has increasingly been recognized. In recent years, multiple studies have explored CRP as a biomarker for prognosis and therapy response, particularly in the context of cancer immunotherapy. In this issue of Cancer Research, Feng and colleagues investigate the role of CRP
-
Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-16 Aaron Seo, Weihong Xiao, Olsi Gjyshi, Kyoko Yoshida-Court, Peng Wei, David Swanson, Tatiana Cisneros Napravnik, Adam Grippin, Aradhana M. Venkatesan, Megan C. Jacobsen, David T. Fuentes, Erica Lynn, Julie Sammouri, Anuja Jhingran, Melissa Joyner, Lilie L. Lin, Lauren E. Colbert, Maura L. Gillison, Ann H. Klopp
Purpose: The human papillomavirus (HPV) is a significant cause of cervical cancer. We hypothesized that detecting viral cell-free HPV DNA (cfDNA) before, during, and after chemoradiation (chemoRT) could provide insights into disease extent, clinical staging, and treatment response. Experimental Design: Sixty-six patients with locally advanced cervical cancer were enrolled between 2017 and 2023. 49
-
HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-16 Naomi Yamamoto, Stephanie Dobersch, Ian Loveless, Annie N. Samraj, Gun Ho Jang, Miki Haraguchi, Liang-I Kang, Marianna B. Ruzinova, Kiran R. Vij, Jacqueline L. Mudd, Thomas Walsh, Rachael A. Safyan, E. Gabriela Chiorean, Sunil R. Hingorani, Nathan M. Bolton, Li Li, Ryan C. Fields, David G. DeNardo, Faiyaz Notta, Howard C. Crawford, Nina G. Steele, Sita Kugel
Purpose: To establish HMGA2 as a marker of basal-like disease in pancreatic ductal adenocarcinoma (PDAC) and explore its use as a biomarker for prognosis and treatment resistance. Experimental Design: We identified high expression of HMGA2 in basal PDAC cells in a scRNAseq Atlas of 172 patient samples. We then analyzed HMGA2 expression, along with expression of the classical marker GATA6, in a cohort
-
Correction: The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness. Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-16 Chellappagounder Thangavel,Ettickan Boopathi,Steve Ciment,Yi Liu,Raymond O'Neill,Ankur Sharma,Steve B McMahon,Hestia Mellert,Sankar Addya,Adam Ertel,Ruth Birbe,Paolo Fortina,Adam P Dicker,Karen E Knudsen,Robert B Den
-
The Landscape of Circulating Tumor DNA (ctDNA) in Appendiceal Adenocarcinoma Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-16 Michael G. White, Mohammad A. Zeineddine, Eleanor A. Fallon, Fadl A. Zeineddine, Julia Dansby, Saikat Chowdhury, Nicholas Hornstein, Abdelrahman Yousef, Mahmoud Yousef, Neal Bhutiani, Yue Gu, Bryan Kee, Arvind Dasari, Michael J. Overman, Kanwal Raghav, Scott Kopetz, Abhineet Uppal, Melissa Taggart, Timothy Newhook, Keith Fournier, Beth Helmink, Leylah M. Drusbosky, John Paul Shen
Purpose: Appendiceal adenocarcinoma (AA) is a rare malignancy with distinct histopathologic subtypes and a natural history with metastasis primarily limited to the peritoneum. Little is known about the molecular pathogenesis of AA relative to common tumors. Experimental Design: We analyzed molecular data for patients within the Guardant Health database with appendix cancer (n = 718). We then identified
-
Pharmacy closures in the USA and Europe Lancet Oncol. (IF 41.6) Pub Date : 2024-12-12 Sharmila Devi
No Abstract
-
TP53 missense allele predisposing to high risk of breast cancer but not pediatric cancers J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-14 Suhair Lolas-Hamameh, Sari Lieberman, Alaa Sarahneh, Tom Walsh, Ming K Lee, Suleyman Gulsuner, Grace Rabie, Rachel Beeri, Amal Aburayyan, Jessica B Mandell, Hila Fridman, Galit Lazer-Derbeko, Tehila Klopstock, Orit Freireich, Amnon Lahad, Mary-Claire King, Ephrat Levy-Lahad, Moien N Kanaan
Pathogenic TP53 germline variants cause young-onset breast cancer and other cancers of the Li-Fraumeni syndrome (LFS) spectrum, but the clinical consequences of partial-loss-of function TP53 variants are incompletely understood. In the consecutive cohort of Palestinian breast cancer patients of the Middle East Breast Cancer Study (MEBCS), breast cancer risk among TP53 p. R181C heterozygotes was 50%
-
Acceptability of an organ inventory for cancer screening across gender identity and intersex status J. Natl. Cancer Inst. (IF 9.9) Pub Date : 2024-12-14 Heidi Moseson, Sachiko Ragosta, Anu Manchikanti Gómez, Jae Corman, Jay Zussman, Bori Lesser-Lee, Sydney Reese, India Rose Carter-Bolick, Juno Obedin-Maliver
Objectives To evaluate the acceptability and performance of an organ inventory as an alternative to asking about gender and/or sex assigned at birth in cancer screening. Methods We fielded an online, self-administered survey to a convenience sample of English- or Spanish-speaking transgender and gender-diverse (TGD), intersex, and cisgender people (>/=15 years) in the US. The survey contained an organ
-
Prior authorisation is can harm patients with cancer in the USA Lancet Oncol. (IF 41.6) Pub Date : 2024-12-12 Karl Gruber
No Abstract
-
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns of acquired resistance to immunotherapy in patients with NSCLC Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-13 Giulia Mazzaschi, Cristina Marrocchio, Lucas Moron Dalla Tor, Ludovica Leo, Maurizio Balbi, Gianluca Milanese, Ganiyat A.R. Adebanjo, Bruno Lorusso, Gregorio Monica, Monica Pluchino, Roberta Minari, Simona D'Agnelli, Elisa Cardinale, Fabiana Perrone, Paola Bordi, Alessandro Leonetti, Roberta E. Ledda, Mario Silva, Sebastiano Buti, Giovanni Roti, Stefano Bettati, Federico Quaini, Marcello Tiseo, Nicola
Purpose: To uncover the underpinnings of acquired resistance (AR) to immunotherapy (IO), we determined whether distinctive clinico-pathological, radiomic and peripheral blood (PB) immune-inflammatory features reflect oligo- and systemic (sys)-AR in advanced NSCLC patients undergoing immune checkpoints inhibitors. Experimental Design: On 105 consecutive IO-treated advanced NSCLC, PB immunophenotypes
-
Complete remissions of HER2-positive trastuzumab-resistant xenografts using a potent [225Ac]Ac-labeled anti-HER2 antibody-drug radioconjugate Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-13 Jessica Pougoue Ketchemen, Fabrice Ngoh Njotu, Hanan Babeker, Alissar Monzer, Emmanuel Nwangele, Anjong Florence Tikum, Nikita Henning, Nava Hassani, Sarah Frye, Randy Perron, Chris Byrne, Candice Didychuk, Qi Qi, Laura Bannister, Alireza Doroudi, Humphrey Fonge
Purpose: There is overwhelming interest to use actinium-225 ([225Ac]Ac) to develop targeted alpha therapies. Antibody-drug conjugates (ADCs) are highly cytotoxic. Combining [225Ac]Ac with ADC to develop an antibody-drug radioconjugate (ADR) [225Ac]Ac-Macropa-trastuzumab-PEG6-DM1, is expected to be more effective than its ADC (trastuzumab-PEG6-DM1) against breast cancer (BC). Experimental design: [
-
Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-13 Jonathan D. Schoenfeld, Nilofer S. Azad, Jacob Gross, Li Chen, Michael J. Overman, Katrina Kao, Latifa F. Jackson, Donna Brunnquell, Xiangning Bu, Christina Coppola, Ping Guan, Jennifer Lee, David Sims, Rebecca Fuchs, Jason L. Weirather, Kathleen L. Pfaff, Lauren Gunasti, Srin Ranasinghe, Stanley R. Hamilton, Victoria Wang, Peter J. O'Dwyer, Catherine J. Wu, Scott J. Rodig, David R. Patton, Lyndsay
Purpose: Mismatch repair deficient (dMMR) tumors have demonstrated favorable responses to immune checkpoint inhibition targeting PD-1. However, more in-depth identification of predictors of response could further refine patient selection for immunotherapy treatment. Experimental Design: We undertook integrated evaluation performed on samples collected from 28 of 42 patients enrolled on the NCI-MATCH
-
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies Clin. Cancer Res. (IF 10.0) Pub Date : 2024-12-13 Jason J. Luke, Karen Gelmon, Lillian L. Siu, Victor Moreno, Jayesh Desai, Carlos A. Gomez-Roca, Matteo S. Carlino, Russell K. Pachynski, Rasha Cosman, Quincy Siu-Chung. Chu, Silvia Damian, Giuseppe Curigliano, Rachel Tam, Xianling Wang, Chandrika Jeyamohan, Lily Wang, Li Zhu, Julia Santucci-Pereira, Danielle M. Greenawalt, Josep Tabernero
Purpose: To evaluate linrodostat mesylate, a selective, oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, combined with nivolumab ± ipilimumab in advanced solid tumors and hematologic malignancies. Patients and Methods: In this phase 1/2 study, patients received once-daily (QD) linrodostat (part 1 [escalation], 25-400 mg; part 2 [expansion], 100 or 200 mg) plus nivolumab (480 mg every [Q] 4 weeks
-
A metabolic pathway for improving adoptive cellular therapy Cancer Cell (IF 48.8) Pub Date : 2024-12-12 Christina M. Scheffler, Paul A. Beavis, Phillip K. Darcy
In this issue of Cancer Cell, Qiu et al. use single-cell metabolic analysis to identify reduced mannose metabolism as a previously unknown feature of exhausted T cells. This metabolic pathway can be targeted to enhance memory and persistence of adoptively transferred T cells, resulting in improved anti-tumor efficacy.
-
Advances in liquid biopsy: From exploration to practical application Cancer Cell (IF 48.8) Pub Date : 2024-12-12 Catherine Alix-Panabières, Klaus Pantel
Liquid biopsy has received tremendous attention as a non-invasive approach for detecting and tracking cancer. Here, we discuss the latest work on circulating tumor DNA and circulating tumor cells with respect to clinical applications, including cancer screening, early detection of relapse, real-time monitoring of therapeutic efficacy, and detection of therapeutic targets and resistance mechanisms.
-
Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin Cancer Cell (IF 48.8) Pub Date : 2024-12-12 Heehwa G. Son, Dat Thinh Ha, Yun Xia, Tiancheng Li, Jasmine Blandin, Tomonori Oka, Marjan Azin, Danielle N. Conrad, Can Zhou, Yuhan Zeng, Tatsuya Hasegawa, John D. Strickley, Jonathan L. Messerschmidt, Ranya Guennoun, Tal H. Erlich, Gregory L. Shoemaker, Luke H. Johnson, Kenneth E. Palmer, David E. Fisher, Thomas D. Horn, Shadmehr Demehri
-
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1 Cancer Cell (IF 48.8) Pub Date : 2024-12-12 Zhen Yang, Xinpeng Liu, Jun Zhu, Yangyang Chai, Boyi Cong, Bo Li, Wanfeng Gao, Ye Hu, Mingyue Wen, Yanfang Liu, Li Fu, Xuetao Cao
-
Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host Cancer Cell (IF 48.8) Pub Date : 2024-12-12 Maria F. Gonzalez-Aponte, Anna R. Damato, Tatiana Simon, Nigina Aripova, Fabrizio Darby, Myung Sik Jeon, Jingqin Luo, Joshua B. Rubin, Erik D. Herzog
-
Breaking the mold: Unconventional T cells in cancer therapy Cancer Cell (IF 48.8) Pub Date : 2024-12-12 Yan-Ruide Li, Kuangyi Zhou, Yichen Zhu, Tyler Halladay, Lili Yang
Unconventional T cells, including invariant natural killer T (iNKT) cells, gamma delta (γδ) T cells, and mucosal-associated invariant T (MAIT) cells, play important roles in both innate and adaptive immunity. These cells respond to tumors rapidly and influence the tumor microenvironment (TME). Recent advances in understanding their biology, as well as the development of novel therapeutic approaches
-
Cytokines in cancer Cancer Cell (IF 48.8) Pub Date : 2024-12-12 Courtney T. Kureshi, Stephanie K. Dougan
Cytokines are proteins used by immune cells to communicate with each other and with cells in their environment. The pleiotropic effects of cytokine networks are determined by which cells express cytokines and which cells express cytokine receptors, with downstream outcomes that can differ based on cell type and environmental cues. Certain cytokines, such as interferon (IFN)-γ, have been clearly linked
-
Stressing the importance of circadian time in treatment responses Cancer Cell (IF 48.8) Pub Date : 2024-12-12 Katja A. Lamia
Circadian disruption increases cancer risk, but connections between circadian clocks and cancer biology are diverse and depend on tumor type. In this issue of Cancer Cell, Gonzalez-Aponte et al. demonstrate that circadian timing of glucocorticoid exposure affects glioblastoma growth. These findings underscore the importance of timing in designing therapeutic interventions.
-
Hodgkin lymphoma therapy: minimising clinical and biological harms Lancet Oncol. (IF 41.6) Pub Date : 2024-12-12 Simonetta Viviani, Corrado Tarella
No Abstract
-
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial Lancet Oncol. (IF 41.6) Pub Date : 2024-12-12 Icro Meattini, Maria Carmen De Santis, Luca Visani, Marta Scorsetti, Alessandra Fozza, Bruno Meduri, Fiorenza De Rose, Elisabetta Bonzano, Agnese Prisco, Valeria Masiello, Eliana La Rocca, Ruggero Spoto, Carlotta Becherini, Gladys Blandino, Luca Moscetti, Riccardo Ray Colciago, Riccardo A Audisio, Etienne Brain, Saverio Caini, Marije Hamaker, Jure Verbancic
BackgroundOptimal therapy following breast-conserving surgery in older adults with low-risk, early-stage breast cancer remains uncertain. The EUROPA trial aims to compare the effects of radiotherapy and endocrine therapy as single-modality treatments on health-related quality of life (HRQOL) and ipsilateral breast tumour recurrence (IBTR) outcomes in this population. MethodsThis non-inferiority, phase
-
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study Lancet Oncol. (IF 41.6) Pub Date : 2024-12-12 Anna Santarsieri, Emily Mitchell, My H Pham, Rashesh Sanghvi, Janina Jablonski, Henry Lee-Six, Katherine Sturgess, Pauline Brice, Tobias F Menne, Wendy Osborne, Thomas Creasey, Kirit M Ardeshna, Joanna Baxter, Sarah Behan, Kaljit Bhuller, Stephen Booth, Nikesh D Chavda, Graham P Collins, Dominic J Culligan, Kate Cwynarski, George A Follows
BackgroundProcarbazine-containing chemotherapy regimens are associated with cytopenias and infertility, suggesting stem-cell toxicity. When treating Hodgkin lymphoma, procarbazine in escalated-dose bleomycin–etoposide–doxorubicin–cyclophosphamide–vincristine–procarbazine–prednisolone (eBEACOPP) is increasingly replaced with dacarbazine (eBEACOPDac) to reduce toxicity. We aimed to investigate the impact
-
Colorectal cancer incidence trends in younger versus older adults: an analysis of population-based cancer registry data Lancet Oncol. (IF 41.6) Pub Date : 2024-12-12 Hyuna Sung, Rebecca L Siegel, Mathieu Laversanne, Chenxi Jiang, Eileen Morgan, Mariam Zahwe, Yin Cao, Freddie Bray, Ahmedin Jemal
BackgroundPrevious studies have shown that colorectal cancer incidence is increasing among younger adults (aged <50 years) in multiple high-income western countries in contrast with stabilising or decreasing trends in incidence in older adults (aged ≥50 years). This study aimed to investigate contemporary colorectal cancer incidence trends in younger adults versus older adults. MethodsColorectal cancer
-
Optimising therapy and avoiding overtreatment in breast cancer Lancet Oncol. (IF 41.6) Pub Date : 2024-12-12 N Lynn Henry
No Abstract